Cancer and venous thromboembolism

Journal of B.U.ON.

Volumn 10, Issue 4, 2005, Pages 483-489

  Grudeva Popova, Janet ^a  

^a University of Hospital   (Bulgaria)

Author keywords

Cancer; Prophylaxis; Thrombosis; Treatment

Indexed keywords

ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; ANTITHROMBIN III; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 5A; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 8A; BLOOD CLOTTING FACTOR 9A; COUMARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; PROTEIN C; PROTEIN S; THROMBIN; THROMBOPLASTIN; VITAMIN K GROUP; WARFARIN;

ACTIVATED PROTEIN C RESISTANCE; AGING; ANTICOAGULATION; ANTINEOPLASTIC ACTIVITY; ANTIPHOSPHOLIPID SYNDROME; BLEEDING; CANCER HORMONE THERAPY; CATHETER THROMBOSIS; CLINICAL TRIAL; COMORBIDITY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MONITORING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TARGETING; ENDOTHELIAL DYSFUNCTION; GENE MUTATION; GENETIC ANALYSIS; GENETIC RISK; GENETIC SUSCEPTIBILITY; HEPARIN INDUCED THROMBOCYTOPENIA; HIGH RISK PATIENT; HUMAN; HYPERHOMOCYSTEINEMIA; INDWELLING CATHETER; LONG TERM CARE; LOW DRUG DOSE; MALIGNANT NEOPLASTIC DISEASE; MUTATIONAL ANALYSIS; PATHOGENESIS; PATHOPHYSIOLOGY; PATIENT CARE; POSTOPERATIVE THROMBOSIS; PREVALENCE; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SHORT COURSE THERAPY; THROMBOCYTE ACTIVATION; TREATMENT PLANNING; VASCULAR ENDOTHELIUM; VENOUS THROMBOEMBOLISM;

EID: 33344473211     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Abramson N, Abramson S. Hypercoagulability: Clinical Assessment and Treatment. South Med J 2001; 94: 1013-1020.
2. Rosendaal FR. Risk factors for venous thrombotic disease. Thromb Haemost 1999; 82: 610-619.
3. Amiral J. New approaches for biological diagnosis in thrombosis and haemostasis. Eur Clin Lab 1992; 11: 29-35.
4. Dati F. New aspects of laboratory testing for hemostasis disorders. IFCC 1996; 8: 94-99.
5. Trousseau A. Phlegmasia alba dolens. Clinique medicale de l'Hotel-Dieu de Paris 1865; 3: 654-712.
6. Blom JW, Doggan CJM, Osanto S. Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2004; 293: 715-722.
7. Baron JA, Gridley G, Weiderpass E et al. Venous thromboembolism and cancer. Lancet 1998; 351: 1077-1080.
8. Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation 2003; 107: 117-121.
9. Prandoni P, Lensing AWA, Piccioli A, Bernardi E. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100: 3483-3488.
10. Lee AY, Levine MN, Baker RI et al. Low-molecular weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 249: 144-153.
11. Rosendaal FR, Doggen CJM, Zivelin A et al. Geographic distribution of the 20210 G to Aprothrombin variant. Thromb Haemost 1998; 79: 706-708.
12. Thaler E, Lechner K. Antithrombin III deficiency and thromboembolism. Clin Haematol 1981; 10: 369-390.
13. Tait RC, Walker ID, Reitsma PH et al. Prevalence of protein C deficiency in the healthy population. Thromb Haemost 1995; 73: 87-93.
14. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346: 1133-1134.
15. Den Heijer M, Rosendaal FR, Blom HJ et al. Hyperhomocysteinemia and venous thrombosis: a meta-analysis. Thromb Haemost 1998; 80: 874-877.
16. Ginsberg JS, Wells PS, Brill-Edwards P et al. Antiphospholipid antibodies and venous thromboembolism. Blood 1995; 86: 3685-3691.
17. Monreal M, Fernandez-Llamazares J, Perandreu J et al. Occult cancer in patients with venous thromboembolism: which patients, which cancers. Thromb Haemost 1997; 78: 1316-1318.
18. Brandjes DPM, Heijboer H, Butler HR et al. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal vein thrombosis. N Engl J Med 1992; 327: 1485-1489.
19. Ginsberg JS. Management of venous thromboembolism. N Engl J Med 1996; 335: 1816-1828.
20. Dolovich L, Ginsberg JS. Low molecular weight heparins in the treatment of venous thromboembolism: an updated meta-analysis. Vessels 1997; 3:4.
21. von Tempelhoff GF, Harenberg J, Niemann F et al. Effect of low molecular weight heparin (certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: a prospective randomized double-blind trial. Int J Oncol 2000; 16: 815-824.
22. ENOXACAN Study Group. Efficacy and safety of enoxaparin versus unfractioned heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. Br J Surg 1997; 84: 1099-1103.
23. Rasmussen MS. Preventing thromboembolic complications in cancer patients after surgery: a role for prolonged thromboprophylaxis. Cancer Treatment Rev 2002; 28: 141-144.
24. Kakkar AK. Thrombosis and Cancer. Hematol J 2004; 5: S20-S23.
25. Goerner A. The influence of anti-clotting agents on transplantation and growth of tumor tissue. J Clin Lab Med 1930; 16: 369-372.
26. Schunemann HJ, Munger H, Brower S et al. Developing evidence-based guidelines for the ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: S174-S178.
27. Haas S. From theory to practice - new anticoagulant agents. Hematology 2005; 1: 225-230.
28. Lee AYY. Venous Thromboembolism and Cancer: New Insights and Therapy. Hematology 2004; ASH-EPB: 450-456.
29. Hyers TM, Agnelli G, Hull RD et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2001; 119: 176S-193S.